Irritable bowel syndrome treatment startup OrphoMed has completed a series A round co-led by Takeda Ventures and New Enterprise Associates.
US-based irritable bowel syndrome treatment developer OrphoMed has closed $39m a series A round co-led by Takeda Ventures, the corporate venture capital arm of drug manufacturer Takeda.
Venture capital firm New Enterprise Associates co-led the round with Takeda Ventures, while existing investors Pappas Capital, Relativity Healthcare Partners and Mario Family Fund also took part.
The funding will be used to progress OrphoMed’s lead candidate, ORP-101, a molecule used to treat irritable bowel syndrome with diarrhoea (IBS-D) through clinical development.
ORP-101,…
